戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1         AIT reduces symptoms, but has also a disease-modifying effect.
2 ired to demonstrate that a ligand can have a disease-modifying effect.
3 rio of MF, there is no clear indication of a disease-modifying effect.
4 c markers, suggesting a potential pathogenic disease-modifying effect.
5 that inhibition of LRRK2 activity can have a disease-modifying effect.
6 evodopa in combination with carbidopa had no disease-modifying effect.
7 ion, suggesting a potential miR-23a-specific disease-modifying effect.
8 EM106B haplotype, potentially underlying its disease-modifying effect.
9  of airway tissue remodeling suggestive of a disease-modifying effect.
10 ence at week 80 implies that levodopa had no disease-modifying effect.
11 Huntington's disease, even in the absence of disease-modifying effects.
12  unlikely to provide both anticonvulsant and disease-modifying effects.
13 mouse models of human tauopathies could have disease-modifying effects.
14  support the hypothesis that pramipexole has disease-modifying effects.
15  over the past 30 years, with at best modest disease-modifying effects.
16 so evidence that cholinergic agents may have disease-modifying effects.
17                       Methotrexate does have disease-modifying effects.
18 dosing, and investigated potential long-term disease-modifying effects.
19 psy (FTRE) may demonstrate treatment-related disease-modifying effects.
20 neffective in one-third of patients and lack disease-modifying effects.
21  to exert not only a symptomatic but also, a disease-modifying effect against AD.
22  undermined by the absence of evidence for a disease-modifying effect and presence of arguably superi
23 nterpretation of open-label studies positing disease-modifying effects and further research into FTRE
24 e experts supporting a clinically meaningful disease-modifying effect, and others judging insufficien
25 in the discovery of new drugs with potential disease-modifying effects; and (4) implantation of fetal
26  drug delivery platform like this can elicit disease modifying effects as well as facilitate long-ter
27 on of dopaminergic therapies does not convey disease-modifying effects but does reduce disability.
28 enefits that were consistent with a possible disease-modifying effect, but early treatment with rasag
29 re the contribution of IL-10(+) ILC2s in the disease-modifying effect by allergen immunotherapy.
30     These therapies are hypothesised to have disease-modifying effects by reducing the concentration
31 tion of APOE-associated AD/ADRDs, as well as disease-modifying effects conferred by several variants
32      Determining whether levodopa also has a disease-modifying effect could provide guidance as to wh
33                                   Defining a disease-modifying effect could radically change the way
34 olinesterase inhibitor may reach the maximal disease-modifying effect for both amyloid pathology and
35                               An additional, disease-modifying effect has been suspected from studies
36 erous candidate genes for susceptibility and disease-modifying effect have also been studied in the l
37 the subthalamic nucleus (STN-DBS) may have a disease modifying effect in early Parkinson's disease (P
38 he potential to provide both symptomatic and disease modifying effects in Alzheimer's disease patient
39 tes splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal Muscular Atrophy (SM
40  with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats i
41 uria versus placebo, providing support for a disease-modifying effect in patients with IgA nephropath
42 en possible to determine that any drug has a disease-modifying effect in PD.
43 loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes,
44 p acutely after trauma may have a beneficial disease-modifying effect in subjects with acute TBI.
45 ese compounds have failed to have a reliable disease-modifying effect in subsequent clinical trials.
46 plotypes to determine their associated HIV-1 disease-modifying effects in a large well-characterized
47 de improved cognitive functioning as well as disease-modifying effects in Alzheimer's disease.
48 ly relevant time point after injury can have disease-modifying effects in epilepsy.
49 2X7 receptor has anticonvulsant and possibly disease-modifying effects in experimental epilepsy.
50 he diseased brain, providing symptomatic and disease-modifying effects in Parkinson's disease.
51 examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease.
52 e been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease.
53                                         This disease-modifying effect is both antigen-specific and an
54  population-specific HIV-1 transmission- and disease-modifying effects is a striking example.
55 , long-term effectiveness of AIT, complement disease-modifying effects observed in SQ grass SLIT-tabl
56             This study aimed to evaluate for disease modifying effects of sodium selenate treatment i
57 e normalized to control levels, indicating a disease-modifying effect of acidified water.
58 flect improved disease control and suggest a disease-modifying effect of AIT.
59           New evidence was published for the disease-modifying effect of allergen immunotherapy in te
60 ntitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne m
61 ings do not provide support for a subsequent disease-modifying effect of inhaled corticosteroids afte
62 plify its clinical effect and supplement the disease-modifying effect of new treatments to slow down
63 ata support the putative neuroprotective and disease-modifying effect of STN-DBS in a mechanistically
64 holinesterase inhibitor therapy suggesting a disease-modifying effect of these drugs.
65                       These results indicate disease-modifying effects of 4-AP beyond symptomatic the
66 n humans may have implications for potential disease-modifying effects of BCHE-modulating agents in t
67 biomarkers are less powerful for quantifying disease-modifying effects of compounds that target AD pa
68 ically, there is increasing evidence for the disease-modifying effects of glucocorticoids, which make
69                 In parallel, we examined the disease-modifying effects of microbiota in HNSCC, throug
70 rapy (AIT) in allergic rhinitis (AR) and the disease-modifying effects of the SQ grass sublingual imm
71 e pathophysiology, course, and potential for disease-modifying effects of treatment.
72 related interstitial lung disease, elicits a disease-modifying effect on SSc vasculopathy, such as fo
73  as a racemic mixture (GL-RM), and potential disease-modifying effects on neuronal morphology.
74 s may have dual effects in RA, with a modest disease-modifying effect (requiring confirmation) and si
75 eria or secondary end points reflective of a disease-modifying effect such as complete remission rate
76 oriatic disease and might even have additive disease-modifying effects to conventional immunomodulato
77                                        These disease-modifying effects were dose-dependent, with a br